AU2004212160B2 - Crystalline forms of pitavastatin calcium - Google Patents

Crystalline forms of pitavastatin calcium Download PDF

Info

Publication number
AU2004212160B2
AU2004212160B2 AU2004212160A AU2004212160A AU2004212160B2 AU 2004212160 B2 AU2004212160 B2 AU 2004212160B2 AU 2004212160 A AU2004212160 A AU 2004212160A AU 2004212160 A AU2004212160 A AU 2004212160A AU 2004212160 B2 AU2004212160 B2 AU 2004212160B2
Authority
AU
Australia
Prior art keywords
stands
dihydroxy
fluorophenyl
cyclopropyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004212160A
Other languages
English (en)
Other versions
AU2004212160A1 (en
Inventor
Fritz Blatter
Kai-Uwe Schoning
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004212160(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of AU2004212160A1 publication Critical patent/AU2004212160A1/en
Assigned to NISSAN CHEMICAL INDUSTRIES LTD. reassignment NISSAN CHEMICAL INDUSTRIES LTD. Request for Assignment Assignors: CIBA SPECIALTY CHEMICALS HOLDING INC.
Application granted granted Critical
Publication of AU2004212160B2 publication Critical patent/AU2004212160B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU2004212160A 2003-02-12 2004-02-02 Crystalline forms of pitavastatin calcium Expired AU2004212160B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03405080 2003-02-12
EP03405080.7 2003-02-12
PCT/EP2004/050066 WO2004072040A1 (en) 2003-02-12 2004-02-02 Crystalline forms of pitavastatin calcium

Publications (2)

Publication Number Publication Date
AU2004212160A1 AU2004212160A1 (en) 2004-08-26
AU2004212160B2 true AU2004212160B2 (en) 2009-05-14

Family

ID=32865094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004212160A Expired AU2004212160B2 (en) 2003-02-12 2004-02-02 Crystalline forms of pitavastatin calcium

Country Status (10)

Country Link
US (15) US20060142582A1 (https=)
EP (3) EP1592668A1 (https=)
JP (13) JP5192147B2 (https=)
CN (3) CN101219992B (https=)
AU (1) AU2004212160B2 (https=)
CA (2) CA2785954A1 (https=)
DE (1) DE202004021379U1 (https=)
PL (1) PL376557A1 (https=)
TW (4) TW201213311A (https=)
WO (1) WO2004072040A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101219992B (zh) * 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
AU2013204129C1 (en) * 2003-12-26 2017-03-02 Nissan Chemical Industries, Ltd. Crystal Form of Quinoline Compound and Process for its Production
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
JP2013516459A (ja) 2010-01-20 2013-05-13 カディラ・ヘルスケア・リミテッド ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法
JP2013536219A (ja) 2010-08-25 2013-09-19 カディラ・ヘルスケア・リミテッド ピタバスタチンカルシウムおよびその調製方法
EP3178812A1 (en) 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2012106584A2 (en) * 2011-02-04 2012-08-09 Dr. Reddy's Laboratories Ltd. Pitavastatin salts
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
PT2751081T (pt) 2011-09-12 2017-04-04 D O O Farma Grs Forma polimórfica de pitavastatina cálcica
EP2768805B1 (en) * 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
CN104860882A (zh) * 2015-05-15 2015-08-26 苗怡文 一种治疗高血脂症的药物匹伐他汀钙组合物
CN104844506A (zh) * 2015-05-15 2015-08-19 苗怡文 一种治疗高血脂症的药物匹伐他汀钙化合物
CN105125504A (zh) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物颗粒剂
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
US10937978B2 (en) * 2016-02-25 2021-03-02 University Of Louisville Research Foundation, Inc. Methods for forming a perovskite solar cell
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN109053568A (zh) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 一种高纯度匹伐他汀钙新晶型及其制备方法
CN113834795B (zh) * 2020-06-08 2024-12-03 上海医药集团股份有限公司 硫酸羟氯喹颗粒水分近红外光谱在线定量模型及其建立方法及检测方法
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
EP4405360A4 (en) 2021-09-23 2025-08-20 Erasca Inc POLYMORPHIC FORMS OF EGFR INHIBITOR
CN116969884A (zh) * 2023-07-28 2023-10-31 河北广祥制药有限公司 一种匹伐他汀钙单晶及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
JPS61171460A (ja) 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
EP0581552B1 (en) 1992-07-31 1998-04-22 Shionogi & Co., Ltd. Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
JP2575590B2 (ja) 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
GB9324931D0 (en) * 1993-12-04 1994-01-26 Pfizer Ltd Glutaramide derivatives
EP0747341B1 (en) 1994-02-25 2002-05-22 Daicel Chemical Industries, Ltd. Process for producing optically active mevalonolactone compounds
JP3558684B2 (ja) 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
JP4281248B2 (ja) * 1998-07-23 2009-06-17 日産化学工業株式会社 キノリン誘導体の製造法及び中間体
JP4749533B2 (ja) * 1999-09-30 2011-08-17 大塚化学株式会社 セファロスポリン結晶
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
PL362981A1 (en) * 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1345903A1 (en) * 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
PL370658A1 (en) * 2002-01-31 2005-05-30 Novartis Ag Process for the manufacture of hmg-coa reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
AU2003231361A1 (en) 2002-04-17 2003-10-27 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of quinoxalinedione derivative anhydride
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
CN101219992B (zh) * 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN100344422C (zh) * 2006-05-11 2007-10-24 朱能国 用人工用材林松木及其板材生产阻燃防潮装饰板材的方法
JP5353678B2 (ja) * 2009-12-17 2013-11-27 トヨタ自動車株式会社 車両の制御装置

Also Published As

Publication number Publication date
US20170022163A1 (en) 2017-01-26
JP5702494B2 (ja) 2015-04-15
EP1592668A1 (en) 2005-11-09
AU2004212160A1 (en) 2004-08-26
JP2014198743A (ja) 2014-10-23
WO2004072040A1 (en) 2004-08-26
US20120101126A1 (en) 2012-04-26
US20090182008A1 (en) 2009-07-16
JP2014205723A (ja) 2014-10-30
CN100374422C (zh) 2008-03-12
JP2018044009A (ja) 2018-03-22
TW200420541A (en) 2004-10-16
TW201345893A (zh) 2013-11-16
JP2019031574A (ja) 2019-02-28
US20060142582A1 (en) 2006-06-29
TW201213311A (en) 2012-04-01
US20140005402A1 (en) 2014-01-02
US20180346425A1 (en) 2018-12-06
TWI485135B (zh) 2015-05-21
DE202004021379U1 (de) 2008-02-21
US8853405B2 (en) 2014-10-07
EP3299359A1 (en) 2018-03-28
JP5500305B2 (ja) 2014-05-21
JP5445713B2 (ja) 2014-03-19
US20190256469A1 (en) 2019-08-22
US20160024010A1 (en) 2016-01-28
US20140364614A1 (en) 2014-12-11
JP2013177466A (ja) 2013-09-09
US20210002227A1 (en) 2021-01-07
JP2014055185A (ja) 2014-03-27
US8557993B2 (en) 2013-10-15
CN101219992A (zh) 2008-07-16
PL376557A1 (pl) 2006-01-09
US20130053413A1 (en) 2013-02-28
JP2014024848A (ja) 2014-02-06
TW201514149A (zh) 2015-04-16
JP5192147B2 (ja) 2013-05-08
JP2016222737A (ja) 2016-12-28
CN102285916A (zh) 2011-12-21
US20180029987A1 (en) 2018-02-01
JP2020169196A (ja) 2020-10-15
CN102285916B (zh) 2015-02-25
EP2500339A1 (en) 2012-09-19
JP2011201915A (ja) 2011-10-13
US20220169614A1 (en) 2022-06-02
CN101219992B (zh) 2011-08-31
CA2785954A1 (en) 2004-08-26
JP2006518354A (ja) 2006-08-10
JP2014062115A (ja) 2014-04-10
CN1747934A (zh) 2006-03-15
CA2513837A1 (en) 2004-08-26
JP5366163B2 (ja) 2013-12-11
JP2015172086A (ja) 2015-10-01
US20200148644A1 (en) 2020-05-14
US20230322680A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US20230322680A1 (en) Crystalline forms of pitavastatin calcium
HK1164873A (en) Crystalline forms of pitavastatin calcium

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NISSAN CHEMICAL INDUSTRIES LTD.

Free format text: FORMER APPLICANT(S): CIBA SPECIALTY CHEMICALS HOLDING INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired